BHRT and Lp(a): What Hormone Therapy Means for Heart Risk

Bioidentical hormone replacement therapy (BHRT) has become an increasingly discussed intervention in managing symptoms of menopause and age-related hormonal decline, particularly in women. Yet its relationship with Lipoprotein(a) [Lp(a)], a recognized independent risk factor for atherosclerosis and cardiovascular disease, is a subject of growing clinical interest. This article offers an in-depth analysis of the scientific evidence regarding how BHRT—and more broadly, hormone replacement therapy (HRT)—affects Lp(a) levels and consequent cardiovascular implications.

• Table of Contents

Understanding Lipoprotein(a) [Lp(a)]

Lipoprotein(a), often abbreviated as Lp(a), is a lipoprotein subclass structurally similar to low-density lipoprotein (LDL). It consists of an LDL-like particle attached by a disulfide bond to apolipoprotein(a).

• Lp(a) levels are largely genetically determined; lifestyle interventions generally have a limited effect.
• High Lp(a) is a well-established independent risk factor for atherosclerosis, myocardial infarction, and stroke.
• It exerts its deleterious effects through both its cholesterol content and prothrombotic properties.

Unlike LDL-C, Lp(a) does not respond predictably to most standard lipid-lowering medications such as statins. Thus, managing high Lp(a) presents a unique clinical challenge.

What is BHRT?

Bioidentical Hormone Replacement Therapy (BHRT) refers to the use of hormones—primarily estrogen, progesterone, and sometimes testosterone—that are chemically identical to those produced naturally by the human body. BHRT is delivered in various forms, including oral tablets, topical creams, sublingual troches, or transdermal patches.

• Bioidentical hormones are most commonly used for men and women experiencing age-related hormonal decline or for alleviating symptoms of menopause.
• Compared to conventional HRT, which often uses synthetic or animal-derived hormones, BHRT is marketed as providing more ‘natural’ hormonal restoration.
• However, both BHRT and conventional HRT act primarily via the same hormonal receptors.

Lp(a) and Cardiovascular Disease Risk

Elevated Lp(a) is considered an independent risk factor for cardiovascular disease (CVD), as it increases the risk of:

• Coronary heart disease and myocardial infarction
• Ischemic stroke
• Peripheral arterial disease

Recent consensus statements by major cardiology societies recommend testing for Lp(a) at least once in a person’s lifetime, especially for those with premature or unexplained atherosclerotic disease, or a family history of high Lp(a).

Why is Lp(a) Hard to Treat?

• Current lipid-lowering therapies like statins have minimal or inconsistent effects on Lp(a).
• Some new biologics (PCSK9 inhibitors, antisense oligonucleotides) are being investigated, but are not widely used yet.
• This enhances interest in other modifiable modulators—such as hormonal therapies.

How Hormones Influence Lp(a) Levels: Mechanisms and Evidence

The interplay between sex hormones and lipoprotein metabolism, including Lp(a), has been studied for decades. Several mechanisms have been proposed to explain how estrogen-based therapies might reduce Lp(a):

• Estrogen may decrease Lp(a) production by the liver
• It may increase hepatic clearance of Lp(a) through upregulation of LDL receptor expression
• Modulation of cholesterol metabolism in the vasculature

Research has demonstrated that estrogen alone and in combination with progesterone can alter Lp(a) levels—but the impact of progesterone is nuanced, as it can attenuate some beneficial effects of estrogen on lipids.

Clinical Evidence: Effects of Hormone Therapy on Lp(a) Levels

Several clinical trials and large observational studies have examined the effects of hormone therapy on Lp(a):

• Estrogen-based therapies lower Lp(a) by approximately 15–25%, with greater reductions in those with higher baseline levels.
• Progesterone may blunt some beneficial lipid changes, particularly the rise in HDL cholesterol.
• Women on hormone therapy show a weaker association between high Lp(a) levels and future cardiovascular events, suggesting that hormone therapy may mitigate some degree of Lp(a)-related cardiovascular risk.

BHRT-Specific Data

Most clinical studies have focused on conventional (often synthetic) hormone therapies. Direct data for BHRT remains limited, but the biological rationale suggests similar trends since both BHRT and conventional HRT act as estrogen receptor agonists.

Key Takeaways:

• Both synthetic and bioidentical estrogens are likely to lower Lp(a); more research is needed for BHRT specifically.
• Individual response may vary depending on baseline Lp(a), genetics, and specific formulation/dosing.

Comparing BHRT to Synthetic Hormones

The major distinction between BHRT and traditional HRT lies in the chemical structure and source of hormones used:

• Bioidentical hormones: Chemically identical to human hormones (e.g., estradiol, progesterone)
• Synthetic/Conventional hormones: May vary slightly in structure (e.g., conjugated equine estrogens, medroxyprogesterone acetate)

Impact on Lipids and Lp(a):

• Studies using both types of estrogens report similar reductions in Lp(a) (15–25% range)
• The route of administration may influence cholesterol metabolism—oral estrogens appear to have a more pronounced effect on Lp(a) than transdermal estrogens.

Progesterone or progestins, when combined, may counteract some favorable changes induced by estrogen, therefore the choice of regimen has clinical importance.

Implications for Cardiovascular Risk Management

Reduction in Lp(a) may contribute to estrogen’s cardioprotective effects, particularly for postmenopausal women with high baseline Lp(a) . However, the overall impact of HRT or BHRT on cardiovascular events remains complex due to other risks associated with hormone therapy, including potential pro-thrombotic effects or cancer risk.

• Women with significantly elevated Lp(a) may benefit from individualized hormone management strategies if appropriate.
• The attenuation of Lp(a)-associated cardiovascular risk among hormone users supports considering hormone status in risk stratification.
• Clinical use should be limited to those with clear indications (such as symptomatic menopause), not solely to lower Lp(a).

Benefit–Risk Balance

Prescribers must balance cardiovascular protection, symptom control, and other risks (e.g., VTE, breast cancer), and avoid use in those with contraindications to hormone therapy.

Safety Considerations in BHRT Use

• Potential adverse effects: thromboembolic disease, breast cancer (depending on formulation and duration), and endometrial hyperplasia (with unopposed estrogen in women with a uterus).
• The lowest effective dose for the shortest duration is generally recommended in major guidelines.
• Individual risk profiles (age, risk for CVD, cancer history) must be carefully evaluated before starting BHRT or any hormone therapy.

Clinical Practice Recommendations

• Consider measuring baseline Lp(a) in women considering BHRT, especially if they have personal or family history of premature cardiovascular disease.
• Use BHRT primarily for management of menopause symptoms, with cardiovascular risk modification as a potential secondary benefit in appropriately selected individuals.
• Monitor lipid panels—including Lp(a) if indicated—regularly during therapy.
• Adopt shared decision-making, thoroughly discussing the benefits and risks with the patient.

Frequently Asked Questions (FAQs)

Q: Will BHRT lower my elevated Lp(a) levels?

A: Estrogen-based hormone therapies (including BHRT) are associated with approximately 15–25% reduction in Lp(a) levels for most women; the reduction may be greater in those with higher starting Lp(a). However, individual responses can vary.

Q: Can BHRT be used solely to lower Lp(a) and prevent heart disease?

A: Hormone therapy should not be started with the sole purpose of lowering Lp(a) or preventing heart disease, due to the balance of risks and benefits. Use is generally reserved for menopausal symptom relief with secondary cardiometabolic benefits as a consideration.

Q: Does progesterone in BHRT reduce the benefit of estrogen on Lp(a)?

A: Progesterone (or progestins) may blunt some of the beneficial effects of estrogen on lipid parameters, particularly HDL cholesterol. However, most studies show that Lp(a) reduction is preserved regardless of progestin co-administration, although regimen-specific differences exist.

Q: Should all women with high Lp(a) take BHRT?

A: No. Hormonal therapy is not recommended for everyone. Decisions must consider personal and family history, timing relative to menopause, cardiovascular risk, and individual preference.

Q: Is there a difference between bioidentical and synthetic hormones regarding Lp(a)?

A: Both bioidentical and conventional HRT lower Lp(a) to a similar extent, as both act on estrogen receptors. However, the route of administration may be important; oral estrogens tend to have a more pronounced effect on Lp(a).

Conclusion: Looking Forward

Bioidentical hormone replacement therapy—and hormone therapy more broadly—offers modest but clinically meaningful reductions in Lp(a) for symptomatic menopausal women, potentially mitigating some of the excess cardiovascular risk attributed to high Lp(a). Nevertheless, therapy should be tailored, balancing the cardiovascular benefits against potential adverse effects, and guided by current best evidence and patient preference. As research evolves, a more personalized approach to hormone management and cardiovascular risk reduction is likely to emerge.